Exclusive conversations with CEOs and founders defining the cannabis economy.
In the first of a new three-part series, Graham Woodward, Chief Medical Officer at Releaf, sat down with Business of Cannabis to discuss what it takes to scale a medical cannabis clinic from three patients to tens of thousands in just two years.
Dr Stefan Broselid, Founder and Scientific Lead of ECS Restore, has filed a patent application for a non-cannabinoid formulation designed to treat dysfunction in the endocannabinoid system (ECS), moving his research from scientific hypothesis towards a meaningful commercial proposition.
Whilst expressing empathy with patients impacted by the recent German crackdown on cannabis flower, the head of the country’s leading wholesaler is bullish about its prospects – with orders up 50% since its purchase by Canadian cannabis giant High Tide.
The imminent launch of the first new European cannabis-based pharmaceutical for over five years could not have been better timed, it seems.
Irish pharmaceutical cannabis manufacturer Dunbar Pharmaceuticals has today launched the first plant-derived dronabinol active ingredient into the UK market.
Just over a month ago, one of the most interesting and potentially consequential hearings in the history of US cannabis policy began.
Investment in the cannabis industry has long been dominated by specialists, speculators, and momentum traders, but that is beginning to change.
Last year (fiscal year 2024/2025), Canada’s legal cannabis industry recorded revenues of CA$5.5bn, according to the latest figures from Statistics Canada.
Cannabis Europa London returns on 26-27 May 2026, bringing together operators, investors, clinicians and policymakers from across the global cannabis industry for two days of main stage debate, exhibition, and networking.
